Abzena, Alira Health, and Oncodesign Launch Specialist Services Consortium

Abzena (Cambridge, UK), Alira Health (Framingham, MA), and Oncodesign (Dijon, France) have announced that, with the launch of DRIVE™-Biologics, they are entering into a consortium to offer their partners “synergy and expertise in their biologics drug discovery and development programs.”

The companies state that their joint service offering will leverage Abzena’s strength in design and developability and cell line development through to commercial manufacturing of biologics, alongside Oncodesign’s pharmacology expertise in oncology and inflammatory diseases, and Alira Health’s full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.

“We are delighted to formalize our relationship with Oncodesign and extend it to Alira Health to bring our partners access to therapeutic innovation. Our shared mission to put patients at the center of all that we do means we are continuing to innovate and drive effective therapies to align to the needs of our partners,” commented Campbell Bunce, PhD, Chief Scientific Officer of Abzena.